Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Day#2 = another RED candlestick. Hopefully Monday brings a green one.
have to wonder if the previous 3 days with RED candlesticks on the DayChart were people who got wind that this Filing was coming..
$3.25 needs to hold next week. previous resistance, new support..
1st Earnings release next week. 11/02/2016
Everbridge, Inc. is expected* to report earnings on 11/02/2016 after market close. The report will be for the fiscal Quarter ending Sep 2016. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14.
Read more: http://www.nasdaq.com/earnings/report/evbg#ixzz4OMc3mfWz
Neat theory on poison pill. but for me I've seen it way too many times over the years where investors have to come up with elaborate stories to justify what could be a pretty bad and detrimental move for Longs by companies often enriching themselves.
Maybe this is the way it's done, i.e. Poison Pill.. but if the company is so concerned about protecting investors, why wouldn't they come out with a PR to accompany this information.. explaining that they continue to have investors in mind and as a safeguard we are doing this, etc.
don't they realize this type of news looks horrible and people will sell, just to be safe? don't they care?
I don't know. maybe I foolishly sold a $35k position at rock bottom. though times I've held on with hope only to be stung.. well. cash is king and I took the cash.
time will tell.
Profit on Warrants loss on Common... I'll be happy to buy back when this settles.. but could only see todays official announcement and some misinformation around it as creating SP pressure.
Will see the rest of my common set to fill here at 3.50 and 3.52
actually 3.50 just filled
Personally I can't think of one time where Dilution has ever had a positive effect on a share price.
OUT all my warrants today from .7785 shame I didn't sell at peak.
OUT around 7k COMMON and there are a few more up at 3.50 and 3.52 if anyone wants them. luckily got out others higher but from an avg $1 higher.
maybe I'm a fool and I panicked. after reading that interview the other day.. I was planning on holding super long time. After todays silent news and next meeting months away.. can't see how the SP will do anything but fall.
what am I missing?
I certainly thing that post on Twitter about how great an investment opp KTOV is without mentioning anything about todays bad news roped a few unsuspecting retails to buy this dip today.
We will see.
one more weak hand out. You guys can now reap all the profits for yourselves.
good luck
Nice 30% move yesterday. I personally bought quite a bit in the .40s with anticipation that a deal is in the works.
I figure an intent to partnership was formed months ago around same time the Polymer business was sold for $10M
All this contingent on Yield10 results in the fast field trials.
That data is in now and it's only a matter of time before we hear on this data and it's direct affect on partnership talks.
All highly speculative and purely just another opinion.
Caveat Emptor, but my PT is well over $1.50 as a starting point if Data is good.
If it's not good and a partnership deal is not imminent than... well... as they said they have a runway until late 2017 with regards to cash in hand.
That would put an all or nothing on next years crop.
Based on all the messages I'm hearing and actions of the company I think, and personally hope, this story plays out over the next couple weeks.
For exercise reasons it's in the interest of a couple larger insiders to close a deal by December 31st, 2016
This gives a near enough Deadline of Oct 31st to announce such a deal
Investor Relations call from last night
http://ir.metabolix.com/events.cfm
http://edge.media-server.com/m/p/2qtxmemw
Historically speaking should open around .20 - .33 and this could easily be months down the road.
anything more than that,, count yourself lucky and take the bonus! on the 1st Short Cover rally that will eventually come on the day. don't get greedy.. you can always buy back if the company turns real.. errr again.
the game is up and the show is over.
Ladd was a crook, ripping off shareholders long before he roped in Mcafee to his game.
feel sorry for both Longs and shorts here. days will turn into weeks, weeks to months.. can think of two examples in the last 5 years where it just dragged out
That doesn't mean the hit the other stocks took in similar situs will apply here, just taking a guess based on what I've seen before. Unfortunately one of those I was long in, in 2011.. took a $40K+ hit.. so I know the pain.
It halted at $11.60 and opened back up at 1.30 before eventually going to .10 a month or so later
.. for sure though, the sooner longs just accept the loss get back to sleeping well and put this behind them the better.
good luck to all
Crazy article on Seeking Alpha about corrupt management at WATT....
$EVBG Florida Hurricane Season Citizen alerting = $12M Everbridge Statewide Contract signed earlier this year
http://www.orlandosentinel.com/news/local/os-mass-notification-lake-20160921-story.html
KNOW what you own!
Heike Sederoff named Yield10 Advisory Board 1 month ago.
I expect news within the month on data she's been analyzing with regards to this years Fast Field trials which were conducted on the Canadian Harvest. Just My Opinion!
09/28/2016
(GlobeNewswire) - Metabolix, Inc. (NASDAQ:MBLX), today announced that Heike Sederoff, Ph.D. Professor, Department of Plant and Microbial Biology at North Carolina State University (NC State) has been named to the Yield10 Bioscience Scientific Advisory Board (SAB). Yield10 Bioscience, the crop science venture launched by Metabolix in 2015, is focused on developing proprietary, breakthrough technologies to create step-changes in yield for major food and feed crops to enhance global food security.
We are pleased to welcome Dr. Sederoff to our Scientific Advisory Board, said Oliver Peoples, Ph.D., chief scientific officer. We have collaborated with Dr. Sederoff and her team at NC State on advanced metabolic engineering technologies for improving crop yield using camelina as a model system. We look forward to Heikes contributions in her role as an advisor to our team as we work in 2016 to translate our approach to boosting crop yield and drought resistance to agriculturally significant crops and move from greenhouse to field trials.
We have collaborated with the Yield10 team on grants supporting advanced research to improve seed and biomass yield in oilseed crops, said Heike Sederoff, Ph.D. Professor, Department of Plant and Microbial Biology at North Carolina State University. Our work focused on yield improvement using camelina has produced encouraging results and we look forward to continue working with the Yield10 team to engineer new plant yield traits applicable to important feed and food crops.
Heike Sederoff, Ph.D. is currently Professor in the Department of Plant and Molecular Biology and Systems and Synthetic Biology Chair at North Carolina State University. Dr. Sederoffs recent research has focused on the study of plant systems and synthetic biology. She has used metabolic engineering methods to increase carbon assimilation and allocation in an oilseed crop and in model plant species including marine algae. Dr. Sederoff received an M.S. in Biochemistry and a Ph.D. in Plant Biochemistry at University of Gttingen, Germany.
Earlier in 2016, Yield10 Bioscience named Michael Lassner, Ph.D., former vice president of trait discovery at Dupont Pioneer and Danny Schnell, Ph.D., Professor and Chair of the Department of Plant Biology at Michigan State University, to its SAB.
For more information, visit www.metabolix.com. (MBLX-G)
For more information on Yield10 Bioscience, visit Yield10.
Metabolix & NC State Enter into Worldwide, Exclusive License Agreement for Advanced Crop Technologies
WOBURN, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Metabolix, Inc. (NASDAQ:MBLX), today announced that it has entered into a worldwide, exclusive license agreement with North Carolina State University ("NC State") for advanced crop science technology used to improve crop yield. This technology was developed by Dr. Heike Sederoff, Professor, Department of Plant and Microbial Biology and colleagues at NC State. This license will expand the intellectual property portfolio being assembled by Yield10 Bioscience, the crop science venture launched by Metabolix in 2015. Yield10 is focused on developing proprietary, breakthrough technologies to create step-changes in yield for major food and feed crops to enhance global food security.
"The technology developed by Dr. Sederoff and her team at NC State holds significant promise for developing new yield traits based on advanced metabolic engineering methods to improve carbon capture and selectively control carbon partitioning in plants," said Oliver Peoples, Ph.D., chief scientific officer. "Work on these yield traits has been done using camelina, a model system for oilseed crops such as canola and soybean. We look forward to continuing our collaboration with NC State and advancing the technology through to development and commercialization."
"Dr. Sederoff's technology is an innovative approach to identifying new ways to boost yield in agriculturally significant crops by focusing on de-bottlenecking crucial pinch points in plant metabolism," said Dr. Kultaran Chohan, Ph.D., Associate Director with the Office of Technology Commercialization and New Ventures ("OTCNV"). "This license covers technology that is complementary to the approach Yield10 is taking and is currently being evaluated for boosting yield in oilseed and other crops."
About NC State's Office of Technology Commercialization and New Ventures
The OTCNV facilitates the commercialization of innovations and discoveries made at NC State. Comprised of a team of professionals with business, academic, and legal backgrounds, the OTCNV connects researchers, industry, and the entrepreneurial community in order to license NC State inventions. With an emphasis on supporting economic growth and enabling societal well-being, these commercialization efforts have resulted in over 500 products brought to market and the launch of over 100 startup companies.
About Metabolix
Metabolix, Inc. is implementing a strategic plan under which the Company has wound down its legacy PHA biopolymer business and Yield10 Bioscience will become its core business with a focus on developing disruptive technologies for step-change improvements in crop yield. Yield10 is leveraging Metabolix's extensive track record of innovation based around optimizing the flow of carbon intermediates in living systems. Yield10 is working on new approaches to improve fundamental elements of plant metabolism through enhanced photosynthetic efficiency and directed carbon utilization. Yield10 is advancing several yield traits in development in crops such as camelina, canola, soybean and corn. The Company is based in Woburn, MA.
For more information, visit www.metabolix.com. (MBLX-G)
For more information on Yield10 Bioscience, visit Yield10.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, expectations regarding the progress of Yield10, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.
http://ir.metabolix.com/releasedetail.cfm?ReleaseID=991444
Yield10 Bioscience Crop Enhancement Info:
CAMBRIDGE, Mass., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Metabolix, Inc. (NASDAQ:MBLX) announced today the launch of Yield10 Bioscience to develop and commercialize innovations in crop science. Yield10 is developing proprietary, breakthrough technologies to improve yield in major crops based on its "T3" transcriptome targeted metabolic engineering platform.
According to the Food and Agricultural Organization of the United Nations, the global population is projected to grow from 7 billion to 9 billion by 2050 driving the need for a 70% increase in food production. The projected rise in population, as well as growing pressure on water and land resources requires new agricultural solutions to increase yield in food, feed and energy crops worldwide.
"The launch of Yield10 Bioscience is a step in our ongoing efforts to refocus our crop science program and create a pathway for potential industry collaborators and investors to participate in the development and commercialization of these exciting technologies," said Joseph Shaulson, president and CEO of Metabolix. "Yield10 has assembled an impressive array of technologies and intellectual property, and has generated promising early data showing the potential of the platform to produce step changes in crop yield. We look forward to engaging with partners and advancing the technology in agriculturally significant crops to build value in Yield10, while providing innovative new solutions to enhance global food security."
Yield10 is leveraging the microbial diversity found in nature to increase carbon fixation and eliminate bottlenecks in plant carbon metabolism, and has developed a transcriptome targeted metabolic engineering systems approach to achieve step changes in crop yield.
Crop yield must ultimately address the twin challenges of enhancing basic carbon fixation via photosynthesis and optimizing the conversion of that fixed carbon into the food product of interest, typically the seed. From a metabolic engineering perspective this is analogous to optimizing the carbon conversion yield in microbial systems, an area where Metabolix is a world leader.
"Over the last 15 years Metabolix has secured significant government grants to develop innovative strategies to direct the flow of carbon in plant systems to produce PHA biopolymers and chemicals. Building on the core competencies and intellectual property developed through these efforts, we have shifted our focus to engineering novel gene systems in plants through a platform we refer to as 'Transcriptome Targeted Metabolic Engineering' or T3 to produce significant increases in crop yield," said Oliver Peoples, Chief Scientific Officer. "Through the development of technologies that allow us to increase the efficiency of CO2 fixation through photosynthesis and its conversion into plant matter, we have shown encouraging yield improvements in camelina seed and switchgrass biomass production. We look forward to building on this research to enable step changes in seed production in critical food crops including soybean and canola."
Crops utilizing the C3 photosynthetic system such as soybean, canola, rice, wheat and potato account for more than 90% of global food production. C3 crops utilize the rubisco enzyme for CO2 fixation in a system that is 50% less efficient than CO2 fixation in C4 plants such as corn and sugarcane. Evolution has solved some of the limitations of the C3 system through the development of a unique cell structure in the green tissue of C4 plants. The global need for increased food production has focused resources on scientific approaches to convert C3 plants to the C4 photosynthetic system, which is extremely challenging. Metabolix recognized the critical importance of deploying metabolic engineering systems in C3 crops to leverage the enormous diversity of carbon conversion systems available from the microbial world. By combining this approach with proprietary advanced crop transcriptome network analysis, Yield10 created the T3 platform and is now working to deploy a series of proprietary gene systems to increase carbon capture and fixation in C3 plants. Early greenhouse and field trial data show a significant increase in seed yield in camelina, an industrial oil seed crop. Additional field trials are planned to confirm the initial results in camelina, and these gene systems are now being inserted into soybean, canola and rice.
Yield10 is also targeting yield improvement in crops utilizing the C4 photosynthetic system such as switchgrass, sugarcane, corn and sorghum. C4 crops are already much higher yielding and more drought tolerant than C3 crops. Yield10 has leveraged the transcriptome targeting module of its T3 platform to identify three novel global transcription factor (GTF) genes in the bioenergy crop switchgrass that result in increased photosynthesis, increased central metabolism and an overall increase in biomass yield. The Yield10 team has identified corresponding genes in both C3 and C4 food and feed crops, and is currently testing these genes in sugarcane and exploring partnerships to advance the technology in corn.
The Yield10 technology platform has generated promising early results in camelina and switchgrass. While there is significant work ahead to transfer and validate these results and transfer the Yield10 technologies to agriculturally significant crops such as soybean, canola, corn, sugarcane, wheat, rice and others, the Yield10 team is excited about the potential for generating step changes in crop yield.
To access a slide deck providing an overview of Yield10 Bioscience, please visit http://ir.metabolix.com/events.cfm.
EVBG more than just Terror threat Communications Service
http://www.cloudpro.co.uk/collaboration/6342/how-everbridge-saved-south-western-ambulance-service-80000
Acquisition History & IPO with Acquisitions Strategy in Mind
Cloudfloor 2011
Vocal (UK offices) 2014
Nixle – Jan 2015
https://www.google.fr/search?q=everbridge+acuisition&rlz=1C1AFAB_enFR519FR519&oq=everbridge+acuisition&aqs=chrome..69i57j0.5336j0j4&sourceid=chrome&ie=UTF-8#q=everbridge+acquisition
On their IPO news they list Acquisitions as part of strategy for money raised
http://bostinno.streetwise.co/2016/09/16/everbridge-ceo-on-90m-ipo-stock-price-acquisitions-strategy/
Not saying pending news, nor Imminent.. but seems likely in foreseeable future as they look to expand products and land grab across the Globe as part of their Aggressive Growth Strategy
Jobs Page for EVBG = expanding with Sales Focus
http://chk.tbe.taleo.net/chk05/ats/careers/searchResults.jsp?org=THREEN&cws=1
$MBLX up 25% today on anticipation. love it. 500K shares ain't bad
Recent news has been trickling with more to come. In My Opinion.
IMO.. they have data and that is why the latest addition to the board took place. Question is, how good the data is and if it's good enough to attract an instant partner.
wish I could moderate this board again to get rid of all the Polymer stuff I stuck up here last year..
NOVAN Inc. Not Noven!
Fast Field trials have been underway for Yield10. Harvest should be coming in now & would expect data on Yield & Traits for this discovery exercise in the next 3-6 weeks.
defining moment "post micro-bead" is upon us
Heike Sederoff Ph.D. Yield10 Advisory Board
http://ir.metabolix.com/releaseDetail.cfm?ReleaseID=991063
Nice Volume. Are we rich yet! ;)
didn't sell a share today.. will wait this one a few months.
Holding shares + warrants.
good luck to us
Well if this is capitulation.. took the opportunity to double down last few days.
workable average now to go green on any news. maybe turns to nothing or even worse .001
What was that plan?
about the only positive notes I can find:
1. Short interest down from 42K to 36K shares
1. Stock just popping it's head over the 20 SMA, which when looking at Volume over the past 15 days could be accounted for by these 6K shorts covering their position. lol
search for news comes up with Nothing
search on Royalstone Information Technology Inc comes up with Nothing
nothing very exciting here
anything noteworthy anyone can add?
disclosure: for my Sins I'm LONG from $'s higher. would buy here to get my average much closer to todays price.. but that would be based on nothing more than Hope, not much of a strategy & plan. really.
----------------
eFuture Holding Inc. formerly eFuture Information Technology Inc. (eFuture) is a holding company. The Company operates through its subsidiary eFuture (Beijing) Royalstone Information Technology Inc. The Company is a provider of software and mobile social shopping network services to China’s retail and consumer goods industries. eFuture provides a one-stop end-to-end integrated portfolio of software and services for the front-end supply chain from factory to consumer on seven verticals: fast moving consumer goods (FMCG) department store shopping mall grocery logistics specialty store and online retailers. eFuture operates three business lines: software solutions myStore and omni-channel cloud service. Software Solutions represent eFuture’s traditional software business. myStore is a mobile social network connecting physical stores and its local consumers. Omni-channel Cloud Services includes myStore-driven omni-channel solutions and digital labor cloud services.
I know a guy, who's an investor, who's wife is a Doctor; he had her evaluate/analyse RLYP indepth... I'll get on this for you on Monday and see if I can get her to give her take on KITOV
yep RBNEWS spot on. you were right now that I think about it.. the guy was challenging a deletion, now that I remember.
that all is immaterial.
luckily there some buyers now. I kept seeing these 5K and 6K blocks popping up under $3 and thought it was some insider dumping.
I reckon I was just being paranoid now.
need to see some strength off this bottom bounce though... or really where is the bottom?
FWIW- I picked my shares right back up soon as it got through 3.00... for a .06 difference.
Not risking what I'm not prepared to lose in the long term
Good weekend to all. and good luck.
Interesting L2 action. Blocks kept popping up in the 5K, 6.5K numbers to show a 3.00 wall to get through.. but then they disappear as they start to fill.
very strange.
2 quesitons I have.
1. why and who has sold over 100K shares today under $3.00 ( ok I sold 2,200 that I've bought at 3.22 yesterday at 2.98 as I'm not about to ride those down to 2.50 or less. ) happy to buy them back if we break through and hold $3.00
..still holding 12K from over $4.00 = not good
2. why delete valid posts like that one guy just put up? it wasn't angry, aggressive nor slanderous.. just stating a fact.
*I was really impressed over the last couple weeks to read back through all the useful info on this board. If I were to think that only the positive and none of the negative is allowed here.. it would change the perception I have.
you guys have a ton of good info and I believe should allow both sides to post.
Just my opinion
Chart and L2.. well chart sucks, but L2 showing people buying here and more on the Bid than ASK.
18K shares on the BID 2.94 / 2.95 we should move up from here.
not going to knee jerk near recent lows.. but gosh won't stick around if we dip $2.50
Rather than kool-aid - BuyOut, Going to the Moon, $10 etc. anyone got some cold hard facts here.
Like who many insiders have how many shares that they can dump on the open market??
which, for me, is the only real explanation for this steady and constant drop from $6.50
Well.. I guess OREX is making a little comeback here.. but at least they have an obesity drug currently ( even if it has a tendency to cause suicidal thoughts )..
so maybe ZFGN will catch some sympathy.. even without a drug
maybe this is the place to get in, maybe not. Any stock that goes from $45.00 to $3.27 in a year is serious cause for concern. more likely to go .45 than back to $45.00 in the next year.. Purely speaking from a Statistical perspective.
on a positive note:
How much money does ZFGN have? enough to develop this 'New' drug take through trials??.. or will they need to do a capital raise?
Zafgen abandoned its lead drug, beloranib—an obesity treatment beset by safety problems—and will instead put its resources behind a follow-on preclinical obesity drug that it believes to be much safer. Xconomy spoke with CEO Tom Hughes about the decision, which is terrible news for patients with the rare disease Prader-Willi Syndrome; Zafgen had hoped to win FDA approval of beloranib in Prader-Willi, which would have made it the first marketed drug for the disease since human growth hormone over a decade ago. Shares of Zafgen fell more than 50 percent on the news.
So basically.. any buying of stock here is pure speculation that they will come up with a new drug? and re-invent themselves as a company. Crystal Ball sees a capital raise in future ?
people dying? really. sounds like there is risk for everyone involved with this stock.
scary stock, scary drug.. dangerous weight loss drugs out of fashion. IMO
I came here as the chart popped up on my radar from people pumping it on Twitter... and wanted to put on watch and start to DD. don't like the info I'm seeing.
Anything more than "hope" here? I'm open to being converted, someone enlighten, please.
man..can't believe I sold all under $2.80 typical.
just kidding. too low to sell down here. ask me again on the next haircut
:-P
Nope.. and when you run it through all the technical studies.. it come back worse.
FIBS from the 2.20 to 6.95 run said that the 4.60 fail was a major fail and time to dump.
of course I didn't pull of the techs then as I was too full of hope.
Now it's almost too low to sell. wait a minute. zero is the target on some of these stories, right??? ;)
jk.
I'm not selling but this is getting pretty grim
I thought $3.00 was going to be the bottom.. but the slow bleed continues.
I guess at 2.20 I just double down ( my basis is $5.06 ) and live in denial? as they say.
** I found all the info here useful and encouraging enough to buy some warrants at .77 ... doh
I'm going to say what everyone is thinking.
"This is crap"
i feel better now. maybe tomorrow. oops that's bag holder jargon
Trading at $3.59 today.. what's going to keep it from falling, falling, falling?
Only thing will some sort or PR or Pump.
so toxic at the moment.
someone tell me different, I'm all ears
Check SEC filings.. they issued stock options to pretty much everyone in higher management.
This company is all about selling stock IMO. any website for a supposedly really good company who touts Stock prices, Investor relations, as a major part of their Message..
IMO is a RED Flag.
I dumped this toxic stock on the 3.80 drop.
Chart is UGLY
Next Catalyst? Seems to be holding some ground here.. even in light of the endless SEC docs on Options that came out last week
More eyes on this today and starting to get some airtime.
Yes, some profit taking which is normal on such a run, but held it's line well.
tomorrow will be the proof in pudding... if we can move over $1 and attract more buyers, get over 500K shares. $1.20 - 1.40+ could turn into our new trading range. JMO